According to CNBC-TV18's research analyst Ekta Batra it's SPARC which has emerged as the winner from this deal between Sun Pharma and Merck. They are targeting a portfolio of around 12 drugs in around 100 countries but the focus is expected to be the top 10 countries which are expected to contribute around 80% of revenues.
first published: Apr 13, 2011 02:37 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

